{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=16",
    "query": {
      "intervention": "VEGF",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 829,
    "total_pages": 83,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T12:30:16.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03418532",
      "title": "MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR-mutated NSCLC (Disorder)"
      ],
      "interventions": [
        {
          "name": "MP0250 DARPin® drug candidate, Osimertinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-22",
      "completion_date": "2020-04-24",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03418532"
    },
    {
      "nct_id": "NCT01487044",
      "title": "A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Macugen (Pegaptanib Sodium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-12-07",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487044"
    },
    {
      "nct_id": "NCT00295828",
      "title": "A Pilot Study for the Treatment of Iris Neovascularization With Macugen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Iris Neovascularization",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Pegaptanib Sodium Injection/Panretinal Photocoagulation",
          "type": "OTHER"
        },
        {
          "name": "Panretinal Photocoagulation (PRP)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Hermann Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2006-01",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2008-09-04",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295828"
    },
    {
      "nct_id": "NCT02839707",
      "title": "Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube High Grade Serous Adenocarcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Fallopian Tube Clear Cell Adenocarcinoma",
        "Recurrent Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Fallopian Tube Undifferentiated Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian Undifferentiated Carcinoma",
        "Recurrent Platinum-Resistant Fallopian Tube Carcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma",
        "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Primary Peritoneal Undifferentiated Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 444,
      "start_date": "2017-06-23",
      "completion_date": "2027-05-11",
      "has_results": true,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 907,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02839707"
    },
    {
      "nct_id": "NCT01270542",
      "title": "Avastin for PDR (Proliferative Diabetic Retinopathy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Detachment",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Avastin (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270542"
    },
    {
      "nct_id": "NCT07851025",
      "title": "Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Torvutatug samrotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 950,
      "start_date": "2026-09-16",
      "completion_date": "2033-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Baltimore, Maryland • Billings, Montana + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07851025"
    },
    {
      "nct_id": "NCT00811590",
      "title": "Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peutz-Jeghers Syndrome"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2008-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811590"
    },
    {
      "nct_id": "NCT00049088",
      "title": "Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2002-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049088"
    },
    {
      "nct_id": "NCT00336323",
      "title": "A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Laser Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2006-06",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2016-08-26",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 34,
      "location_summary": "Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336323"
    },
    {
      "nct_id": "NCT00786383",
      "title": "Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "IMC-1121B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1121B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-02",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2013-08-19",
      "last_synced_at": "2026-10-31T12:30:16.857Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Durham, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00786383"
    }
  ]
}